San Antonio Breast Cancer Symposium

SOFT trial endorses selective ovarian suppression in early breast cancer

Posted on: 12/12/2014 - 16:57

SAN ANTONIO – Adding ovarian suppression to 5 years of tamoxifen in women with hormone receptor–positive early breast cancer who remain premenopausal following chemotherapy provides a markedly...

Field of Interest: Oncology

Type: News Item

Adjuvant capecitabine adds no advantage to bisphosphonate in elderly breast cancer patients

Posted on: 12/12/2014 - 14:03

SAN ANTONIO – The combination of capecitabine plus the bisphosphonate ibandronate didn’t improve disease-free survival in elderly women with moderate- or high-risk breast cancers. After 5 years,...

Field of Interest: Oncology

Type: News Item

Pembrolizumab shows efficacy in advanced triple-negative breast cancer patients

Posted on: 11/12/2014 - 14:59

SAN ANTONIO – Roughly one in five women with heavily pretreated, advanced triple-negative breast cancer experienced a durable response to monotherapy using the novel immune checkpoint inhibitor...

Field of Interest: Oncology

Type: News Item

Pembrolizumab shows efficacy in advanced triple-negative breast cancer patients

Posted on: 11/12/2014 - 14:59

SAN ANTONIO – Roughly one in five women with heavily pretreated, advanced triple-negative breast cancer experienced a durable response to monotherapy using the novel immune checkpoint inhibitor...

Field of Interest: Pulmonology

Type: News Item

SOFT trial endorses selective ovarian suppression in early breast cancer

Adjuvant capecitabine adds no advantage to bisphosphonate in elderly breast cancer patients

Pembrolizumab shows efficacy in advanced triple-negative breast cancer patients

Pembrolizumab shows efficacy in advanced triple-negative breast cancer patients

Newsletters

Latest Newsletters

You are here

San Antonio Breast Cancer Symposium

SOFT trial endorses selective ovarian suppression in early breast cancer

Adjuvant capecitabine adds no advantage to bisphosphonate in elderly breast cancer patients

Pembrolizumab shows efficacy in advanced triple-negative breast cancer patients

Pembrolizumab shows efficacy in advanced triple-negative breast cancer patients

Newsletters

Latest Newsletters